Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.
The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. IFM_05-May 2022
Lenalidomide was the primary drug used for maintenance in this study. Key Findings: Due to the risk of secondary cancers identified
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. Key Findings: Research published around May 2022 explored
A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.
If you are looking for guidance based on this study's results:
Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI